Loading…
Underlying
Underlying Price
$6.01
Type
Call
Strike
17
Expiration
Dec 4, 2026
DTE
21d
Moneyness
OTM
Intrinsic
$0.00
IBRX 17 Call Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Nov 13, 2026 | 0d | — | — | 0 | 0 |
| Nov 20, 2026 | 7d | $0.14 | -44.00% | 16 | 236 |
| Nov 27, 2026 | 14d | — | — | 0 | 0 |
| Dec 4, 2026 | 21d | — | — | 0 | 0 |
| Dec 11, 2026 | 28d | — | — | 0 | 0 |
| Dec 18, 2026 | 35d | — | — | 0 | 0 |
| Dec 24, 2026 | 41d | — | — | 0 | 0 |
| Jan 15, 2027 | 63d | $0.22 | -18.52% | 5 | 2,335 |
| Mar 19, 2027 | 126d | $0.70 | -29.29% | 25 | 51 |
| Apr 16, 2027 | 154d | $0.75 | +0.00% | 40 | 76 |
| May 21, 2027 | 189d | $0.67 | -55.33% | 2 | 9 |
| Aug 20, 2027 | 280d | — | — | 0 | 0 |
| Nov 19, 2027 | 371d | $2.25 | -8.16% | 2 | 33 |
| Jan 21, 2028 | 434d | $1.54 | -2.53% | 4 | 988 |
| Mar 17, 2028 | 490d | $2.70 | +25.58% | 26 | 125 |
| Jan 19, 2029 | 798d | $3.95 | +3.95% | 1 | 16 |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.